A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)

Tryfonidis, Konstantinos; Basaran, Gul; Bogaerts, Jan; Debled, Marc; Dirix, Luc; Thery, Jean\\-Christophe; Tjan\\-Heijnen, Vivianne C. G.; Van den Weyngaert, Danielle; Cufer, Tanja; Piccart, Martine; Cameron, David; EORTC\\-Breast Canc Grp

doi:10.1016/j.ejca.2015.10.012

A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)

Date

2016

Authors

Tryfonidis, Konstantinos

Thery, Jean\\-Christophe

Tjan\\-Heijnen, Vivianne C. G.

Van den Weyngaert, Danielle

Cufer, Tanja

Piccart, Martine

dc.identifier.doi

10.1016/j.ejca.2015.10.012

dc.identifier.other

WOS:000368789100016

Publisher

ELSEVIER SCI LTD

DOI

10.1016/j.ejca.2015.10.012

Keywords

Anastrozole , Gefitinib , Metastatic breast cancer , Endocrine resistance

URI

https://openaccess.acibadem.edu.tr/handle/11443/8842

Collections

WOS

Full item page

A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)

Date

Authors

Journal Title

Journal ISSN

Volume Title

dc.identifier.issn

dc.identifier.doi

dc.identifier.other

dc.description.volume

dc.description.issue

Publisher

DOI

Abstract

Description

Keywords

Citation

URI

Collections

Endorsement

Review

Supplemented By

Referenced By